TERMS OF USE
Introduction
Welcome to the Agios PK Deficiency website (“website”). Agios created and maintains this website to provide information to and communicate better with physicians, patients, investors and others who may be interested in learning more about Agios and the products and services it offers. You may use this website, provided you comply with these terms and conditions.
In addition to these terms and conditions, you should also read and be aware of the provisions of our Privacy Policy, which discloses Agios’ practices regarding the collection and use of your personal information, and other policies that govern other parts of our website.
Your Acceptance of These Terms and Conditions
Please take a few minutes to carefully review these terms and conditions. By accessing and using this website you agree to follow and be bound by these terms and conditions. If you do not agree to follow and be bound by these terms and conditions, you may not access, use or download materials from this website.
These Terms and Conditions May Change
Agios reserves the right to update or modify these terms and conditions at any time without prior notice. Your use of this website following any such change constitutes your agreement to follow and be bound by the terms and conditions as changed. For this reason, we encourage you to review these terms and conditions every time you use this website.
These terms and conditions were last revised on July 28, 2018.
This program is only available to residents of the United States.
All testing provided to patients through Anemia ID is paid for by Agios Pharmaceuticals. While Agios provides financial support for this program, all tests and services are performed by PerkinElmer Genomics. Agios receives contact information for healthcare professionals who submit tests under this program and limited de-identified aggregate data.
Anemia ID is sponsored by Agios in partnership with PerkinElmer Genomics. Other laboratories may also offer genetic testing.